The SCOUT MD is the latest step in Merit’s ongoing commitment and leadership in advancing oncology care. SCOUT MD expands Merit’s portfolio of products to optimize oncology for breast and other soft tissue cancers, which includes the SCOUT® Radar Localization system with new SCOUT® Mini Reflector and SCOUT Bx™ Delivery System, and the SAVI® Brachy System.
A first of its kind, the SCOUT MD localization system supports implantation of up to four unique reflector configurations. When implanted within abnormal breast or other soft tissue, the reflectors enable surgeons to pinpoint tumor location in multiple dimensions for more precise excision, minimizing trauma to healthy tissue and helping to reduce the likelihood of re-excision and the emotional and physical pain associated with a second surgery.
Breast cancer is the most common cancer worldwide, representing 12.5% of all new annual cancer cases.1 Lumpectomy (a type of breast conserving surgery) is often performed as treatment. However, an estimated 20% to 30% of women who undergo lumpectomy will need a repeat surgery.2 Localization procedures help surgeons precisely target breast cancer, which may result in more successful surgeries and improved patient outcomes.
“This designation recognizes the significant contribution we believe SCOUT MD can make in oncology treatment,” said
FDA Breakthrough Device Designation is intended to help patients receive timely access to technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. Under the program, the FDA provides priority review and interactive communication regarding device development and clinical trial protocols, through to commercialization decisions.
ABOUT MERIT MEDICAL
Founded in 1987,
TRADEMARKS
Unless noted otherwise, trademarks and registered trademarks used in this release are the property of
CONTACTS
PR/Media Inquiries
Merit Medical
+1-801-432-2864 | sarah.comstock@merit.com
Investor Inquiries
Westwicke - ICR
+1-443-213-0509 | mike.piccinino@westwicke.com
References
- BreastCancer.org. 2023. “Breast Cancer Facts and Statistics.” Last modified
January 18, 2023 . https://www.breastcancer.org/facts-statistics - Havel, Liska et al. 2019. “Impact of the SSO-ASTRO Margin Guideline on Rates of Re-excision After Lumpectomy for Breast Cancer: a Meta-analysis.” Annals of Surgical Oncology 26 (5): 1238 ̶ 1244.
Source:
2023 GlobeNewswire, Inc., source